[Form 3] KalVista Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Arif Bilal, listed as Chief Operations Officer and a director of KalVista Pharmaceuticals, Inc. (KALV), filed an initial Form 3 reporting that no securities are beneficially owned as of the event date 10/06/2025. The filing was signed by an attorney-in-fact on 10/08/2025. This Form 3 records a disclosure obligation under Section 16; instead of listing share ownership or derivative positions, it indicates the reporting person currently holds zero reportable equity or derivative interests.

Positive

• Compliance obligation met with an initial Form 3 filing
• Clear disclosure that no reportable securities are owned as of 10/06/2025

Negative

• None.

Insights

Corporate Governance Analyst

TL;DR: Senior officer and director reports no beneficial ownership of company securities.

The filing shows the Chief Operations Officer and director submitted an initial ownership statement that lists no securities directly or indirectly owned as of 10/06/2025. For governance transparency, a Form 3 is required when a person becomes an officer/director; the absence of holdings is an explicit disclosure rather than an omission.

This creates a clear baseline for future Section 16 reporting; any future acquisition, disposals, or derivative grants will generate subsequent Form 4 or Form 5 filings to track insider activity. Investors and compliance teams will monitor filings occurring shortly after onboarding or compensation events to see if equity grants or purchases are reported.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Arif Bilal

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/06/2025

3. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operations Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Arif Bilal report on the Form 3 for KALV?

The filing states no securities are beneficially owned by Arif Bilal as of 10/06/2025.

What is the significance of filing a Form 3 for KALV insiders?

A Form 3 establishes an initial public record of an insider's ownership under Section 16; this Form 3 reports zero holdings, creating a baseline for future Form 4 or Form 5 updates.

When was the Form 3 for Arif Bilal signed?

The document was signed by an attorney-in-fact on 10/08/2025.

Does the Form 3 show any derivative or option positions for KALV?

No. The filing explicitly states no securities are beneficially owned, and no derivative positions are listed.

Will future filings be required if Arif Bilal receives equity?

Yes. Any future acquisitions, grants, or dispositions would require a Form 4 (or Form 5 when applicable) to report changes in beneficial ownership.